Table 2.
Clinical characteristics of R/R HL patients and response to nivolumab + BV +/- bendamustine.
| Patient ID | Risk | R/R Induction | Status after 2x N-BV | Status after 4x N-BV | Status after 2x B-BV | R/R Consolidation | Post consolidation status | CMR follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | Standard | N-BV + B-BV | PMR | PMR | CMR | RT | CMR | 42 |
| 2 | Standard | N-BV | CMR | CMR | n/a | BEAM | CMR | 38 |
| 3 | Standard | N-BV + B-BV | PMR | PMR | CMR | BEAM | CMR | 34 |
| 4 | Standard | N-BV | CMR | CMR | n/a | BEAM | CMR | 35 |
| 5 | Low | N-BV | CMR | CMR | n/a | RT | CMR | 12 |
| 6 | Standard | N-BV | CMR | CMR | n/a | BEAM | CMR | 23 |
| 7 | Standard | N-BV + B-BV | PMR | PMR | CMR | BEAM | CMR | 20 |
| 8 | Standard | N-BV + B-BV + DHAP-BV (1 cycle) |
PMR | PMR | CMR | BEAM + RT | CMR | 18 |
| 9 | Standard | N-BV + B-BV | PMR | PMR | ProgD | BEAM + RT | CMR | 12 |
| 10 | Low | N-BV | CMR | CMR | n/a | RT | CMR | 25 |
N-BV, nivolumab-brentuximab vedotin; B-BV, bendamustine-brentuximab vedotin; PMR, partial metabolic response; CMR, complete metabolic remission; ProgD, progressive disease.